Another combination is pembrolizumab (PD-1 inhibitor) and axitinib (VEGF-vascular endothelial growth factor inhibitor), used for renal cell carcinoma, leveraging the anti-angiogenic effects of axitinib to enhance anti-tumor immune response. Here, VEGFA is linked to hereditary clear cell renal cell carcinoma.